Skip to main content
KARD logo

KARD · Kardigan, Inc. · Documents

Track KARD — free
$12.68 +0.36 (+2.92%)
Market Cap
$1.15B
Shares
93.60M
Volume · Nov 19 538.43K Avg daily vol (3M) 603.96K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Quarterly report New FY2026 Q3 Net loss $58.57M 10-Q filed Nov 12, 2026 Latest results New Danicamtiv Cohort 2 enrollment completed with $591.4 million cash 8-K filed Nov 12, 2026
2026
Nov 18
Investor event
Danicamptiv six-month data due in Q2 of next year

Kardigan expects six-month Danicamptiv data in Q2 of next year, covering echocardiographic parameters and a directional change in peak VO2. Those correlations could confirm sizing for the 250-patient registrational study. Atasaguat registrational trial details are due in the first half of next year.

4 source passages
That's what we're going to show at the week 26 or the six-month endpoint in Q2 of next year. we'll have those echocardiographic parameters as well as the change in peak VO2 as a directional trend we're properly sized at 250 patient or subject phase three we'll share more data in the first half of next year on the Phase III trial Open the document at this passage
Nov 18
Investor event
Danicamptiv six-month data due in second quarter

Cardigan said six-month data for Danicamptiv in genetic cardiomyopathy comes in the second quarter, with peak VO2 correlations. Week 48 data for Atasaguat in Catalyst AV will confirm AVA and peak VO2, with registrational trial details in the first half of next year. About 80% of mild and moderate aortic stenosis patients show cardiac damage.

5 source passages
starting in the second quarter with Dan and Camtiv At week 26, at six months, and that is the Q2 top-line data So week 48 is going to give us the data we need to confirm AVA and peak VO2 we'll share more details on the registrational trial in the first half of next year What we found is that 80% of patients with mild and moderate aortic stenosis have evidence of cardiac damage. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Three late-stage programs advance with $591.4 million cash

Kardigan advanced three late-stage programs—Danicamtiv, Ataciguat and Tonlamarsen—and expects clinical data in 2027. It reported $591.4 million in cash, cash equivalents and investments and a $230.9 million nine-month net loss.

Net loss $58.57M Diluted EPS -$0.64
Read from the MD&A section
4 source passages
We have three late-stage programs, Danicamtiv, Ataciguat, and Tonlamarsen, in clinical development for indications for which no approved therapies currently exist. We expect to report clinical data from our three late-stage programs in 2027 As of September 30, 2026, we had cash, cash equivalents and investments of $591.4 million. Our net losses were $230.9 million and $135.6 million for the nine months ended September 30, 2026 and 2025, respectively. Open the document at this passage
Nov 12
Current report 8-K
Danicamtiv Cohort 2 enrollment completed with $591.4 million cash

Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial, with topline data expected in 2Q 2027; it also completed ataciguat KATALYST-AV Phase 2b enrollment, with data expected in 2H 2027. Cash was $591.4 million.

Financial results
4 source passages
Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy. Enrollment is complete in Cohort 2 (patients with non-MYH7/TTN variants or a family history of DCM) of the Phase 2b portion of the KINSHIP-DCM clinical trial, and topline data is expected in the second quarter of 2027; the Phase 3 trial is now enrolling across both cohorts. Completed enrollment in Phase 2b ataciguat KATALYST-AV trial; Week 48 topline data expected in 2H 2027 Cash Position: Cash, cash equivalents and investments were $591.4 million as of September 30, 2026, compared to $335.5 million as of December 31, 2025. Open the document at this passage
Nov 6
Current report 8-K
KATALYST-AV enrollment completed; primary endpoint shifts to Week 48

Kardigan completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat for aortic stenosis, moving primary endpoint assessment to Week 48 and topline data to 2H 2027.

Regulation FD disclosure
3 source passages
Kardigan®, Inc. (Nasdaq: KARD), a precision cardiovascular company, today announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS). The primary endpoint in KATALYST-AV of AVC will now be assessed at Week 48, together with additional analyses evaluating change in AVA, LV mass index, stroke volume index, and E/e′. Kardigan expects to provide an update on its Phase 3 development plans in the first half of 2027 and to report Week 48 topline data in the second half of 2027. Open the document at this passage
Sep 30
Current report 8-K Events of Sep 29
Director or officer change, or executive pay, Regulation FD disclosure

Kardigan appointed Kristin Reinke as a Class I director and Audit Committee chair effective September 29, 2026, after Doug Giordano resigned from the board and committee; Reinke will receive stock options valued at $650,000 and cash compensation.

Showing 1–11 of 11 documents
Key facts CIK 2123613 CUSIP 485925101 13F (30d) 86 filings 86 filers Visit website Investor relations